Skip to main content
. 2011 Jan 5;32(7):820–828. doi: 10.1093/eurheartj/ehq502

Table 6.

Safety summary

Safety parameter No. (%) of patients
RLY5016 (N= 56) Placebo (N= 49)
Any adverse event 30 (54) 15 (31)
Gastrointestinal disorders 12 (21) 3 (6)
 Flatulence 4 (7) 0
 Diarrhea 3 (5) 1 (2)
 Constipation 3 (5) 0
 Vomiting 2 (4) 0
Any serious adverse event 2 (4) 2 (4)
 Related serious adverse event 0 0
Any adverse event leading to discontinuation of study drug 4 (7) 3 (6)